Haemostaseology;Hämostaseologie

Internist

Volumn 46, Issue 8, 2005, Pages 873-881

  Schror K ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Antiplatelet drugs; Antithrombotic drugs; Factor Xa; Thrombin; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A; CLOPIDOGREL; COUMARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRUDIN DERIVATIVE; HIRULOG; THROMBIN INHIBITOR;

BLEEDING; DRUG DESIGN; DRUG RESEARCH; HEMOSTASIS; HUMAN; MOLECULAR WEIGHT; REVIEW; RISK BENEFIT ANALYSIS;

DRUG DELIVERY SYSTEMS; DRUG DESIGN; FIBRINOLYTIC AGENTS; HEMOSTASIS; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 23944445893     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-005-1452-3     Document Type: Review

References (30)

1. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86
2. Chew DP, Bhatt DL, Sapp S, Topol EJ (2001) Increased mortality with oral platelet glycoprotein IIb/II-Ia antagonists. A meta-analysis of phase III multicenter randomized trials. Circulation 103: 201-206
3. Davidson BL (2004) Preparing for new anticoagulants. J Thromb Thrombol 16: 49-54
4. Direct Thrombin Inhibitor Trialists' Collaborative Group (2002). Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 359: 294-302
5. Francis JL, Amirkhosravi A (2002) Effect of antihemostatic agents on experimental tumor dissemination. Semin Thromb Hemost 28: 29-38
6. Gustafsson D, Nystrom J, Carlsson S et al. (2001) The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 101: 171-181
7. Heemskerk JWM, Bevers EM, LindhoutT (2002) Platelet activation and blood coagulation. Thromb Haemost 88: 186-193
8. Hermann A, Rauch BR, Braun M, Schrör K, Weber AA (2001) Platelet CD40 ligand (CD40L) - subcellular localization, regulation of expression and inhibition by clopidogrel. Platelets 12: 74-82
9. Herrmann HC, Swierkosz TA, Kapoor S et al. (2002) Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 89: 1293-1297
10. Hirsh J, Dalen JE, Anderson DR et al. (1998) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 114 (Suppl 5): 445S-469S
11. HohlfeldT, Schrör K (2003) Thrombozytenaggregationshemmer, Heparine, Hirudine, Vitamin K-Antagonisten, Thrombolytika. In: Böhm M, Eschenhagen T (Hrsg) Arzneimitteltherapie kardiovaskulärer Erkrankungen. Wiss. Verlagsgesellschaft, Stuttgart, S 210-230
12. Hohlfeld T (2004) Pharmacology of aspirin resistance. In: Schrör K (ed) Aspirin -"resistance" or "nonresponsiveness". Dr.Schrör-Verlag, Frechen, pp 17-32
13. Kokolis S, Clark LT, Cavusoglu E, Marmur JD (2005) Direct thrombin inhibitor use during percutaneous coronary intervention. J Cardiovasc Pharmacol 45: 270-279
14. Leadley RJ, Chi L, Procari AR (2001) Non-hemostatic activity of coagulation factor Xa: Potential implications for various diseases. Curr Opin Pharmacol 1: 169-175
15. Leon C, Alex M, Klocke A et al. (2004) Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood 103: 594-600
16. Mueller MM, Sperl S, Stürzebecher J (2002) (R)-3- amidinophenylalanine-derived inhibitors of factor Xa with a novel active-site binding mode. Biol Chem 383: 1185-1191
17. Nurden AT, Poujol C, Durrieu-Jais C, Nurden P (1999) Platelet glycoprotein IIb/IIIa inhibitors. Basic and clinical aspects. Arterioscler Thromb Vasc Biol 19: 2835-2840
18. Ottervanger JP, Armstrong P, Barnathan ES et al.; GUSTO IV-ACS Investigators (2003) Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina. Circulation 107: 437-442
19. Patrono C, Coller B, Dalen JE et al. (2001) Platelet-active dugs. The relationships among dose, effectiveness, and side effects. Chest 119 (Suppl 1 ): 39S-63S
20. Peter K, Schwarz M, Ylanne J et al. (1998) Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIb/beta3) inhibitors. Blood 92: 3240-3249
21. Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR (1995) Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 92: 962-967
22. Rai R, Sprengeler PA, Elrod KC, Young WB (2001) Perspectives on factor Xa inhibition. Curr Med Chem 8: 101-119
23. Rosen ED (2002). Gene targeting in hemostasis - Factor X. Front Biosci 7: d1915-d1925
24. Schrör K, Gawaz M (2003) Antiplatelet and anticoagulant agents in cardiovascular disease: Basic research and clinical applications. Sem Vasc Med 3: 93-213
25. Schrör K (1997) Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Haemost 23: 349-356
26. Schrör K, Weber A-A (2003) Comparative pharmacology of GPIIb/IIIa antagonists. J Thromb Thrombol 15: 71-80
27. Van Aken H, Bode C, Darius H et al. (2001) Anticoagulation: The present and future. Clin Appl Thromb Hemost 7: 195-204
28. Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schrör K (2002) Towards a definition of aspirin resistance: a typological approach. Platelets 13: 37-40
29. Weber AA, Meila D, Jacobs C et al. (2002) Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors. Thromb Res 106: 25-29
30. Zaman AG, Herlft G, Worthley SG, Badimon JJ (2000) The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 149: 251-266